The Teva Pharmaceuticals and Sanofi drug, duvakitug, showed statistically significant and clinically meaningful results in a Phase 2b study in ulcerative colitis and Crohn’s disease. The drug is part of an emerging class of therapies that target TL1A, a protein involved in signaling that drives inflammation.
Eli Lilly’s Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly’s 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
FDA approval of blockbuster AbbVie drug Rinvoq makes it the first oral therapy for moderately to severely active Crohn's disease. The regulatory nod is the seventh for the drug, which belongs to a class of therapies called JAK inhibitors.
AbbVie drug Skyrizi is now approved for Crohn’s disease, making it the first treatment for the disorder that addresses a particular protein associated with inflammation. In other drug decision news, the Rhythm Pharmaceuticals product Imcivree added the rare disease Bardet-Beidl syndrome as a new approved indication.
Sales of blockbuster Pfizer drug Xeljanz are under pressure from a stronger safety warning placed across that drug’s entire class. In acquiring Arena Pharmaceuticals for $6.7 billion, Pfizer gets a lead compound with a different and potentially safer approach to treating inflammatory conditions.
The timing of the filing appears to allay concerns that the FDA would require completion of a study evaluating the testicular safety of the drug, filgotinib, and thus push its launch date from 2020 to 2021-22, an analyst wrote.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The Human Cell Atlas is a global scientist-led research collaboration is attempting to create a definitive reference guide of cell types, numbers, locations, relationships and molecular components.
Sangamo purchases 53 percent of France-based TxCell, will use zinc finger nuclease technology to develop CAR-Treg cells.
Expanding the oral targeted therapy offerings for GI diseases like IBD, Protagonist Therapeutics plans to go up against the blockbusters like Humira and Remicade
The third generation of Given Imaging‘s PillCam SB got FDA approval today, and President and CEO Homi Shamir said the product should launch in October of this year. The device, a capsule with a camera inside which the patient swallows takes more than 60,000 images before it exits the digestive system. As the Israel-based continues […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.